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Abstract
Pharmacogenomics (PGx)-based personalized medicine (PM) is increasingly utilized
to guide treatment decisions for many drug-disease combinations. Notably, London
Health Sciences Centre (LHSC) has pioneered a PGx program that has become a staple for London-based specialists. Although implementational studies have been conducted in other jurisdictions, the Canadian healthcare system is understudied. Herein,
the multistakeholder perspectives on implementational drivers and barriers are elucidated. Using a mixed-method qualitative model, key stakeholders, and patients
from LHSC’s PGx-based PM clinic were interviewed and surveyed, respectively.
Interview transcripts were thematically analyzed in a stepwise process of customer
profiling, value mapping, and business model canvasing. Value for LHSC located
specialist users of PGx was driven by the quick turnaround time, independence of the
PGx clinic, and the quality of information. Engagement of external specialists was
only limited by access and awareness, whereas other healthcare nonusers were limited by education and applicability. The major determinant of successful adoption at
novel sites were institutional champions. Patients valued and approved of the service,
expressed a general willingness to pay, but often traveled far to receive genotyping.
This paper discusses the critical pillars of education, awareness, advocacy, and efficiency required to address implementation barriers to healthcare service innovation
in Canada. Further adoption of PGx practices into Canadian hospitals is an important factor for advancing system-level changes in care delivery, patient experiences,
and outcomes. The findings in this paper can help inform efforts to advance clinical
PGx practices, but also the potential adoption and implementation of other innovative
healthcare service solutions.
Study Highlights

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
Evidence development for pharmacogenomic (PGx) biomarkers continues to grow,
however, clinical implementation has lagged behind. Key stakeholder perspectives,
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barriers, and drivers of clinical implementation of PGx have been studied in the
United States and Europe, and through siloed approached in Canada.
WHAT QUESTION DID THIS STUDY ADDRESS?
What are the clinical implementational barriers and drivers recognized by multiple
key stakeholders for PGx services in a real-world Canadian healthcare setting?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
This study on multiple stakeholders involved in PGx services, elucidates the different perspectives between major specialist users and major specialist nonusers of PGx
services. As well, elicits the perspectives of other nonuser healthcare professionals
and patients. In doing so, an appropriate framework for successful clinical implementation of PGx is understood.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR
TRANSLATIONAL SCIENCE?
Clearly understanding the core values of specialists whom PGx is largely applicable
will confer greater adoption of the services. Moreover, understanding the perspectives of other key stakeholders will streamline the implementational process for future
prospective sites, build primary care awareness, and continue to meet the needs of
patients. Together, generating evidence for changes in PGx funding and governance
in Canada.

I N T RO D U C T ION
Pharmacogenomics (PGx), a component of personalized
medicine (PM), is the study of how genetic factors can affect drug responses.1 Used in concert, patient and disease-
specific biomarkers can inform a more precise stratification
of patients into different response/risk groups, enabling
more appropriate drug prescription and more precise dose
selection.2,3 PGx biomarkers can broadly be classified as
prognostic, predictive, or both.4 Prognostic biomarkers
provide insight into the course of a disease through the
evaluation of the disease-
specific genome.4 These biomarkers, commonly seen in a cancer setting, determine the
presence of therapeutically targetable driver mutations.5
Alternatively, predictive biomarkers are determined by
analyzing the patient-specific genome and help discern
whether a treatment will be helpful or harmful to that specific patient.4

TH E P RO B L E M
Annually, adverse drug reactions (ADRs) kill about 15,000
Canadians and costs the healthcare system over CDN $13
billion.6 Given the impact of ADRs and growing evidence
for genome-
informed prescription,7–9 current trial-
and-
error methods should be eager to give way for a more effective approach to therapeutic intervention. The dramatic
reduction in sequencing costs and optimization of genetic
testing tools have significantly improved the viability of

PGx.10 Although researchers continue to produce evidence
to support gene-
drug relationships,11 the clinical adoption of PGx-based PM has significantly lagged behind.
Implementational barriers and drivers have been well-
studied—issues regarding the validity, cost-effectiveness,
guideline consistency, and lack of physician or patient
awareness, education, and acceptance in this rapidly
emerging field are often cited.12–14 In response, large implementational studies have been conducted in the United
States through the National Institutes of Health-
funded
Implementing GeNomics In pracTicE (IGNITE) program15
and in Europe through the Ubiquitous Pharmacogenomics
(U-PGx) program.16 Complementary large-
scale pan-
Canadian evaluations on PGx implementation in Canada
are scarce. A review of the Canadian PGx implementation literature (Figure S1) yielded siloed approaches where
only one stakeholder group’s perspectives—clinicians, patients, public, or pharmacists—were evaluated (Table 1).
Although relevant, these singular stakeholder perspectives
result in a Canadian healthcare reliant on robust implementation science literature from other jurisdictions—a context
that is not always complementary. Herein, we present the
first report of multistakeholder perspectives from a successful regional PGx program in Canada. Without broader
adoption and deployment of PGx, the requisite critical mass
necessary to affect widespread changes in Canadian PGx
funding and governance, has been hindered. As such, this
study highlights the various perspectives, implementational
barriers, and drivers from a developed PGx program in the
Canadian healthcare system.
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T A B L E 1 Canadian stakeholder perspectives on
pharmacogenomics
Stakeholder
group

Jurisdiction

Year

Reference

Clinicians

Quebec

2018

Amara et al.32

Ontario

2015

Walden et al.31

Ontario

2019

Chan et al.29

Alberta

2021

Asgarpour et al.30

Ontario

2019

Waldman et al.39

Ontario

2013

Loo et al.38

Ontario

2014

Cuffe et al.41

Eastern Canada

2020

Etchegary et al.37

Ontario

2020

Bereza et al.40

Students

Ontario

2014

Lanktree et al.35

Pharmacists

Quebec

2013

de Denus et al.43

Quebec

2020

Petis et al.44

Quebec

2020

Meloche et al.45

British Columbia

2020

Breaux et al.46

Patients

Public

DE V ELO P M E N T A N D LAU NCH
The London Health Sciences Centre (LHSC) PGx program began
in 2008, optimizing treatment using the blood thinner warfarin.
Soon thereafter, the initiative expanded to offer PGx testing for
tamoxifen, an anti-estrogen used for the treatment of breast cancer, broader testing for oral anticoagulants, and cardiovascular
medications.17 Over the years, the focus has been on the systematic integration of additional evidence-based clinically actionable common medications; namely Thiopurine Methyltransferase
(TPMT) testing for gastroenterologists treating inflammatory
bowel disease with Azathioprine, and Dihydropyrimidine
Dehydrogenase (DPYD) testing for oncologists treating
gastrointestinal-
related cancers with fluoropyrimidine-
based
therapies (Figure S2). To date, over 3000 patients have been
provided PGx-guided recommendations.
Recently, a published analysis on the efficacy of pre-emptive
DPYD testing at LHSC (n = 1394), reinforced the known clinical efficacy of DPYD genotyping, but in the limited Canadian
context.18 In this study, a scholarly investigation is conducted
on LHSC’s integration of PGx-based PM into their clinical
practice in an effort to better codify the various stakeholder perspectives on implementation considerations.

ME T H O D S
Stakeholder identification and semi-structured
interviews
Initial interviews with the PGx program’s principal investigator (author R.K.) at LHSC were conducted to identify
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the key stakeholders involved in their care pathway and
program development. These stakeholders could be categorized into four major groups: referring specialists, other
nonreferring healthcare professionals, researchers, and hospital management. Referring specialists (primarily oncologists and gastroenterologists) snowball sampled19 starting
with those frequently referring to the PGx clinic at LHSC.
Nonreferring healthcare professionals were convenience
sampled through recommendations from specialist interviews or identified from the institution’s employee registry.
Finally, researchers and hospital management were identified from the institution’s employee registry and purposefully sampled. To provide structure to interviews within the
same stakeholder group, interview guides were developed.
For each stakeholder group, literature review and informal
discussions with PGx clinic leaders at LHSC guided identification of their general roles, responsibilities, and possible involvement in the PGx clinic. Based on these findings,
interview guides were developed to elicit insights into the
challenges and scaling potential of the PGx clinic, with respect to the day-to-day activities of each stakeholder group.
Individuals were contacted via email and requested to participate in a 30–60 min teleconference interview to identify
their perspectives on PGx-based PM. With informed consent, interviews were recorded and subsequently transcribed
(REB #112204). An a priori interview sample size of ~ 40
stakeholders was selected based on studies conducted in this
field of research.20,21 Interviews continued to be requested
and conducted until information saturation22—totaling 42
stakeholder interviews: both locally around LHSC (n = 35)
and externally (n = 7) at hospitals in three other regions
(Table 2).

Interview data analysis
Using a directed content analysis approach,23 the transcripts
were thematically analyzed, as suggested by the creators of
the Business Model Canvas (BMC),24 through an iterative
and independent coding process by two of the project researchers. First, transcripts were coded to fit into customer
(stakeholder) profiles and value maps. Stakeholder profiles
intend to understand the background of the stakeholder
group and their relation to PGx-based PM. Within stakeholder profiles, subthemes included jobs/roles (day-to-day
activities), gains (existing and possible from PGx-based
PM), and pains (existing and possible from PGx-
based
PM). Value maps elucidated mechanisms to maintain gains
or mitigate pains. Within value maps, subthemes included
products and services (required for day-to-day activities),
gain creators, and pain relivers. Within customer profile and value map subthemes, points were ranked based
on how frequently they arose in interview transcripts. In

2234
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addition to these subthemes, any other pertinent perspectives were noted.
Using the customer profiles and value maps, a BMC was
created24,25 through an iterative process between the two
TABLE 2

Characteristics of stakeholder interview participants

Stakeholder
group

Subgroup

Local
(LHSC)

Referring
Specialists

Oncologists

Nonreferring
Healthcare
Professionals

Nurses

1

Geriatricians

3

Pediatricians

3

Psychiatrists

2

Pharmacists

1

Cardiologists

1

Respirologists

1

Endocrinologists

1

External

4

4

Gastroenterologists

4

2

General Practitioners

5

Research

Pharmacology

5

Admin/
management

Southwest-LHIN
LHSC

1
2

1

Abbreviations: LHIN, Local Health Integration Network; LHSC, London Health
Sciences Centre.

coding researchers. Interview transcripts were reviewed to
ensure nothing was omitted, a visualization exercise of customer profile and value map subthemes was conducted, and
finally subtheme points were integrated into the BMC to finalize customer profiles and value maps.
The BMC, which has previously been utilized to evaluate healthcare technologies and innovations,26,27 is a tool
used to identify the value creation logic and helps determine the quality of a business model. The benefit of using
the BMC is the deconstruction of the business into nine
essential interconnected building blocks graphically represented on the BMC framework. These nine building blocks
can be clustered into four groups. The customer segments
block, which defines the key stakeholders, is derived from
customer profiles. The three blocks for key activities, key
partners, and key resources, collectively, defines how value
is generated from the products/services that are offered by
the business. The value proposition, which defines the core
value-creating traits, is derived from the gain creators and
pain relivers of the value map. The blocks for customer
relationships and channels, which defines how the value-
creating product/service is delivered to key stakeholders, is
derived from the fit between the customer profile and value
map. Finally, are the cost structure and revenue streams,
which in the case of healthcare this is often interpreted as
cost-savings (Figure 1).

F I G U R E 1 Integration of customer profiles, value maps and the business canvas model. Customer profiles (bottom right) defines the pains
and gains associated with each stakeholders’ respective jobs. This information is leveraged to create the value map (bottom left), which defines the
products and services (i.e., key partners, activities, and resources) that will drive the creation of gains and relief of pains (i.e., value). The delivery
of gain creators and pain relivers is derived from the fit between the customer profile and value map, in other words the relationship and channels to
the business offering. Together, these integrate into the business canvas model (top), which defines the value proposition and outlines the necessary
components for value creation
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Survey instrument and patient recruitment
In addition to the four major stakeholder groups identified
for interviews, patients were also highlighted as a relevant
stakeholder group. In order to capture patient perspectives,
a cross-
sectional survey design, with some open-
ended
questions was developed. Questions were created through
discussions with the LHSC PGx clinic staff, and focused
on patients’ prior expectations, experience during, and future recommendations for the clinic’s operations. Patients
surveyed were either patients with cancer that underwent
DPYD testing prior to fluoropyrimidine-based (5-FU) therapy or patients with inflammatory bowel disease that underwent TPMT testing prior to Azathioprine (AZA) therapy.
Genotyped patients were provided a letter of information
and, if consented, received a survey during their routine
clinic visit with respective specialists (REB #114822). The
survey took ~ 15 min to complete, and consisted of multiple
choice, Likert-scaled, and open-ended questions. A total of
18 of 40 surveys distributed were returned, a response rate
of 45%.

RE S U LTS
Recurring and relevant themes, with respect to implementational barriers and drivers of PGx services, within each
stakeholder group are outlined below. Selected quotes from
interviews are presented to highlight these significant themes.

Major considerations from local referring
specialists
Oncologist’s and gastroenterologist’s relationship with the
PGx clinic was long-term and self-service in that patients
identified for pre-emptive genetic testing would be referred.
The PGx clinic would set up an appointment, coinciding with
their specialist visit, to obtain a blood sample. Specialists
gained an awareness of the PGx clinic services and benefits
through professional relationships, internal and external
meetings, and field-specific scientific literature. Buy-in was
also developed through advocacy from “champions”—those
who turn advocacy into action. From the PGx clinic’s perspective, their success was incumbent on allowing specialists
to maintain standard of care, handling the patient education
on PGx, and providing expert genotyping interpretations.
The financial value generation was appraised through cost
savings generated from more precise drug/dose selection and
the reduction of ADR-related expenditures. For example,
1:20 patients potentially receiving 5-FU and 1:300 patients
potentially receiving AZA at LHSC would have severe side
effects without pre-emptive genotyping. Finally, what these
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specialists valued most was the reliability, quality, and speed
of responses. Alternative PGx service offerings through
third-party vendors or similar programs in other jurisdictions
had significantly longer turnaround times—weeks, compared
to days at LHSC. By integrating an internal, independent,
and trusted provider of PGx services, specialists experienced
minimal impositions on their practices, rapid diagnostics that
were concise, accurate, and comprehensive, and enhanced
patient and provider satisfaction (Figure 2).

Major considerations from external
gastroenterologists
The external gastroenterologists (n = 2) were not users of
the LHSC PGx clinic and fell into two categories; those with
another network for genetic testing and those without. Those
without networks either offered TPMT testing through private companies or started low-dose AZA therapy, incrementally increasing while monitoring for ADRs. Most patients
declined the option to pay out of pocket to receive genetic
testing from private laboratory services. In contrast, those
with a network for genetic testing would send a requisition to
their network’s institution, however, their treatment plan was
often delayed by long turnaround times.
I think it’s more of how quickly can the information be relayed, because it is obvious that if I see
a patient in clinic, I do want to get them started
on something today. I won’t have the TPMT
results today. It might take a couple of weeks
depending on how fast the patient gets the blood
work done and how fast the lab actually sends
it and so forth. So that certainly is a potential
limitation, which if it is more mainstream, or
if I could get quicker access to the results and
therefore decide whether or not I could put the
patient on it, it would be more ideal.
(External Gastroenterologist #1).
When asked what the major barriers were to utilize the
LHSC PGx clinic, the two major themes were access and
awareness. For example, when asked if TMPT testing would be
beneficial to their practice.
I would like to have that just because you know,
Azathioprine is at risk of low white blood cell
count or neutropenia, which can lead to infection,
and it’s nice to be able to be more comfortable
that that’s not going to happen for your patient.
So, if I had access to it, at least for my patients in
my population.
(External Gastroenterologist #2).

2236
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F I G U R E 2 Business canvas model for LHSC’s major referring specialists to the PGx clinic. Starting with interview transcripts, the customer
profiles (customer jobs, gain, and pains) and value maps (products/services, gain creators, and pain relivers) were developed. From here, the
nine quadrants of the business canvas model were completed. The value of the PGx clinic for major specialists was driven by the independence
of the clinic, the rapid turnaround time, and how concise yet comprehensive the information provided was. ADR, adverse drug reaction; GI,
gastrointestinal; LHSC, London Health Sciences Centre; LOS, length of stay; PM, personalized medicine

Major considerations from external oncologists
Among the external oncologists (n = 5), four were users of
the LHSC PGx clinic whereas one was not. The nonuser acknowledged the increasing use of prognostic biomarkers for
precision therapies in the field but noted in their personal experience the frequency of DPYD deficiency was rare, occurring
in one in 10,000–20,000 patients. However, this frequency is
inconsistent with observations at LHSC or in the literature.28
The four users of the LHSC PGx clinic discovered the service through professional relationships, word of mouth, or at
patient case discussions. They agreed that dissemination of
information regarding innovative services would be successful during journal clubs, round meetings, or an accredited organization, such as Cancer Care Ontario (CCO). Champions
at their respective institutions appreciated the value of the
pre-emptive DPYD testing.
I think part of it too is that I was in [another city]
where we didn’t have access to it at all, and you’d
see so much more toxicity from these drugs, like
as an oncology trainee, you know, you’re dreading
prescribing [5-FU] in particular because everyone
got sick on it, but you know, coming back [near

LHSC] I was like yes! I have access to this so I can
more comfortably prescribe it, and certainly the
toxicity that I see is much lower here than my residency experience, and I think that’s partly related
to the fact that we do pick up on these intermediate
metabolizers and can adjust things appropriately.
(External Oncologist #1).
When I first came into a practice, we had a patient who we suspected was DPYD, but there
was really, there was no way of testing, and so
you know, we’ve all had at least one patient
that’s had a very extreme severe toxicity. I think
[my colleague] lost a patient from a 5-FU toxicity. So, you know, when you have that happen,
even though there’s a relatively low likelihood,
if there’s something that you can do to screen for
that deficiency or relative deficient in the treatment plans accordingly, I think it’s very valuable.
(External Oncologist #2).
Prior to the LHSC PGx clinic there were no other feasible options, so testing was not offered. The barrier of long
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turnaround times for private or international testing were exacerbated in the context of a cancer diagnosis. Patients from
these external sites had to travel, on average, 1–2 h to receive
testing at LHSC. When asked how patients have appreciated the
service despite inconveniences, such as travel, specialists cited
that ~ 95% of patients were content and compliant. The unwilling patients typically had a physical ailment that precluded
them from traveling such distances. Probing on the potential
integration of DPYD testing into their respective institutions;
external specialists all noted the infrastructure existed but simple disinterest or concerns that deployment would be inherently
challenging caused institutional inertia. A purposed decentralized service model that facilitated local blood collection and
subsequent sample delivery to LHSC for PGx testing was cited
to be more amenable. Extending from this model could be other
major institutions, like LHSC, that facilitate the testing and interpretation for neighboring specialist practices who draw and
deliver the blood samples.
If there was some sort of roll out of trying to expand this program to other centers and show, for
example, a couple hospitals could cover most of
the province.
(External Oncologist #3).
Finally, wheres pre-emptive DPYD testing is not defined as
standard of care they believed it should be. When asked, outside of colleague recommendations, what threshold of evidence
would be required to integrate a novel genetic test into their
practices, the responses included: (a) understanding the nature
of the test; (b) comprehension of incremental risks and benefits;
(c) some preliminary clinical or retrospective evidence to show
clinical benefit; (d) how long has the test been around; (e) an acceptable margin of error; and (f) short and defined turnaround
time.

Other considerations
Among the nonreferring healthcare professionals, the specialists were ambivalent toward the PGx clinic. They felt their
practices had minimal relevance to the clinic but concurred
that more evidence and research into predictive biomarkers
was necessary. Similarly, general practitioners were largely
unaware of the service, primarily learning about it when reviewing specialist referrals. However, if pre-emptive PGx
testing became standard-of-care, these physicians expressed
a positive attitude toward directly referring to the PGx clinic,
if adequately educated.
Among researchers and hospital management, the general
consensus was funding required a larger body of evidence.
“Champions” of the program are those that are motivated
to utilize and advocate for the service and are essential to
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success. These were not restricted to specialists but also
throughout the institution.
I guess on the topic of champions, so I think
within our own environment we had clinical
champions within the medical oncology division who would be actually using the technology. I think we also had champions at sort of
my level, department leaders saying okay I think
this is important for our division and I’m supportive of it, but then we also had administrative
leaders who were supportive as well, so the VP
of the cancer program sort of understood the
potential value of this and was supportive of it,
and so you kind of need champions at multiple
levels for this to happen.
(Hospital Management #1).
In some cases, there was resistance to the adoption of PGx
services.
I think the biggest resistance, even though it’s just
a psychological problem that our institution has,
is space. There’s this perception that if someone
moves into your space, they are somehow going
to take it over or, interfere with other patient care
issues, and so that’s the biggest issue, but we are
able to overcome that.
(Researcher #1).
This resistance was resolved by developing strong working
relationships with referring specialists—importantly, developing an independent service that minimally imposed on their
clinics. Strengthening bonds, such as joint fellowship training between specialist groups and PGx was another tangible
method to reinforce interdisciplinary cohesion.

Patient survey findings
Survey respondents age ranged from 35 to 84 with the most
common age range being 55–64 (TMPT genotyped patients;
n = 4) and 65–74 (DPYD genotyped patients; n = 14). There
were three major takeaways from the patient stakeholder
group. First, all patients were extremely satisfied with the
service (Figure 3). Patients citied thoroughness in explanations, professionalism, appointment brevity, and overall
knowledge as defining traits (Table 3). Second, only four
of 18 patients were driving under 30 min to attend their appointment (Table 3). Finally, whereas the willingness to pay
(WTP) dollar amount varied from under $100 (n = 4), between $100 and $200 (n = 6), and to over $200 (n = 3), no
patients cited their unwillingness to pay for the PGx services
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F I G U R E 3 Additional patient
responses to survey questions. Questions
were scaled on a 5-point Likert scale. Some
patients did not answer every question
(n = 15–18). All patients had a positive
experience, and one patient felt neutral
about their level of confusion after receiving
their test results

(Table 3). This contrasted the experiences of external gastroenterologists, who stated patients were unwilling to pay
out-of-pocket for PGx testing.

DI S C U S S IO N
Other studies conducted in the Canadian context have focused on a single stakeholder group. With respect to clinician
perspectives, four studies have been previously conducted.
Two of these studies highlighted the lack of physician
awareness, despite guideline recommendations, for human
leukocyte antigen genotyping prior to carbamazepine and allopurinol treatment—which in some haplotypes can result
in fatal dermatological complications.29,30 Another study
focused on psychotropic medications and found the majority of Canadian physicians who previously ordered at least
one PGx test, to understand the PGx report.31 However, this
understanding and satisfaction declined from clinician scientists, to psychiatrists, to general practitioners. Similarly,
we found these primary care physicians to be unaware of
PGx services, yet confident in utilizing them if adequately
educated. Finally, a survey of over 400 physicians in Quebec
corroborated these findings, citing family physicians were
less likely to adopt PGx testing due to the lack of information and clinical guidelines.32 They also found that for
many physicians, adoption required regulatory approval
from Health Canada, scientific literature demonstrating the

clinical benefit, recommendations experts and peers, and
clinical guidelines.32 Nonusers in our study also cited the
requirement of scientific evidence, but in general focused
less on regulations of guidelines and more on their individual understanding to sway future use of PGx services. With
respect to the other jurisdictions, both IGNITE and U-PGx
have conducted evaluations on physician readiness for PGx
implementation.33,34 In the first instance, IGNITE surveyed
285 physicians across five sites and found two-thirds felt
their PGx-related training was inadequate.33 Similarly, U-
PGx surveyed 70 physicians across seven European countries and found that lack of PGx-related knowledge was a
significant barrier if the application of testing in clinical
practise.34 Resolving the lack of awareness and understanding in Canada will likely require a coordinated effort between health authorities for current physicians and medical
schools for future physicians. In fact, despite students’ positive attitude towards PGx,35 Canadian medical schools have
historically lagged behind in PGx curriculum compared to
pharmacy schools.36
Among Canadians, past studies have found general agreeability with PGx technology,37 increased amenability to less
invasive sampling,38 and that many patients utilizing private
services do not disclose findings to their healthcare providers.39 With respect to our work, Bereza et al. assessed the
WTP of general Ontarians in Canada and found WTP to increase for faster turnaround time.40 Moreover, Sinead et al.
showed in the same geography that patients with cancer were
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TABLE 3
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Survey results from patients genotyped at LHSC PGx clinic

Test

Age
range

Sex

Travel
time

Clinic
expectations

Amount willing
to pay

DPYD

35–44

F

>2 h

Greatly exceeded

>$200

Kind, friendly, informative team, efficient. Thorough
understanding of benefits.

35–44

M

30–45 min

Greatly exceeded

Prefer not to say

Switched from blood to saliva sample; explained the
legalities –I was overjoyed!

45–54

N/A

1.5–2 h

Greatly exceeded

$100–$200

On time, minimal waiting, very professional doctor and
staff, explained things really well.

55–64

M

45 min–1 h

Greatly exceeded

$100–$200

Got in quickly. Things were explained well by doctor
and nurse, who were truly kind.

55–64

F

>2 h

Greatly exceeded

$100–$200

Very quick from referral to appointment, answered
every question I had.

55–64

M

>2 h

Exceeded

>$200

Very knowledgeable, answered all questions. Could
testing be done at same time as blood draw?

65–74

M

>2 h

Exceeded

$100–$200

I was treated so well, appointment was so fast.

65–74

F

1.5–2 h

Exceeded

>$200

Staff was very pleasant and helpful. Explained the
nature of his study.

65–74

M

30–45 min

Greatly exceeded

<$100

Appointment on time with no waiting, very
knowledgeable staff.

65–74

F

<30 min

Exceeded

$100–$200

So well explained. Quick appointment and painless.

65–74

M

1–1.5 h

Greatly exceeded

Prefer not to say

Spent time to explain and felt better once I understood
the concept and how it helps me.

65–74

M

<30 min

N/A

Prefer not to say

Very quick appointment and explained everything well.

65–74

F

1.5–2 h

Matched

Prefer not to say

Very informative, pleasant and positive.

75–84

F

<30 min

N/A

<$100

Very informative and easy to understand.

18–24

F

<30 min

Matched

<$100

Explained research and process being done, passionate,
caring, informative team.

55–64

F

45 min–1 h

Greatly exceeded

N/A

Kind, explained the research, explained the procedure.

55–64

N/A

30–45 min

Exceeded

<$100

Fast appointment, on time, efficient staff. Impressed to
find out drug and dosage can be optimized.

55–64

M

1–1.5 h

Greatly exceeded

$100–$200

Staff were wonderful at explaining the testing and
answered questions in full.

TMPT

Summarized comments

Abbreviations: DPYD, Dihydropyrimidine Dehydrogenase; LHSC, London Health Sciences Centre; N/A, not available; PGx, pharmacogenomics.

willing to pay a median $1000 to $2000, and wait upwards
of 2 weeks for their results if it meant a clinical benefit.41
Although our study limited the upper threshold of WTP at
>$200 CAD, almost all our surveyed patients stated some
WTP. In contrast, a study in the United States surveying 869
patients found close to half (42%) were unwilling to incur
costs of PGx testing.42 From those who were willing to pay,
most would pay a maximum of $250 (87%) or $100 (58%).42
An important difference to note is, about half of the patients
surveyed had no previous exposure to the clinical benefit of
PGx testing, whereas, in our study, all patients had undergone
testing. Therefore, the WTP may depend on the understanding and exposure to the potential benefits of PGx.
Other Canadian studies—
three in Quebec and one in
British Columbia—assessed the overall feasibility of disseminating PGx services through pharmacists.43–46 Although our

study evaluated the deployment of PGx services through a
large outpatient hospital, the broader adoption of PGx may
hinge on leveraging primary care physicians and pharmacists.
Many factors played into the successful implementation
and continued growth of LHSC’s PGx clinic. Education,
awareness, advocacy, and efficiency were crucial pillars to
its success. Implementation was incumbent on champions
of the service and tied closely into education and advocacy.
Those who do not understand, or are unaware of, the benefit
of pre-emptive PGx testing, will not be inclined to participate. Therefore, effective knowledge translation and provisioning of education on the evidence surrounding PGx needs
to be disseminated through appropriate channels within the
institution. These channels should reach not only the relevant specialists, but also others involved in the care pathway, including hospital administration and nurses.20,47 Once
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a substantive support network has been established, a suitable workflow can be developed to simultaneously maximize
efficiency and minimize resistance. Specialist users of the
PGx service were highly motivated because of the clinic’s
independence, clear and comprehensive interpretation, and
quick turnaround time. Utilizing identified awareness channels, such as hospital rounds or through agencies, like CCO,
to promote the benefits of PGx services will be important
for attracting champions and continuing to expand the geographic scope.
This study is not without limitations. First, conducting
interviews rather than surveys with healthcare stakeholders
resulted in a small sample size. Although the findings are
consistent with other large survey-based studies, an enhancement to the study would be to gather perspectives from across
Canada. Second, self-reported bias may have played a factor. Eliciting response at multiple timepoints (i.e., before and
after genotyping) and from a large sample sizes can identify
and reduce the impact of these biases. Nonetheless, understanding these key implementational drivers and barriers
faced by LHSC’s PGx clinic will help guide the implementation of similar offerings elsewhere—together, building a
proof of concept for standard of care pre-emptive PGx testing
and governmental reimbursement.
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